loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Gujarat Themis Biosyn Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Gujarat Themis Biosyn Ltd. 25 May 2026 15:13 PM

Q4FY26 & FY26 Result Announced for Gujarat Themis Biosyn Ltd.

Pharmaceuticals company Gujarat Themis Biosyn announced Q4FY26 & FY26 results

Financial Highlights:

  • Income from Operations (Revenue): For Q4FY26, Income from Operations stood at Rs 4,423.30 lakh, registering a growth of 1.99% QoQ compared to Rs 4,336.82 lakh in Q3FY26. On a YoY basis, it increased by 17.22% from Rs 3,773.62 lakh in Q4FY25.
  • Annual Income from Operations: For FY26, Income from Operations was reported at Rs 16,582.28 lakh, showcasing a growth of 9.96% YoY against Rs 15,079.99 lakh in FY25.
  • Total Income: In Q4FY26, Total Income reached Rs 4,515.41 lakh, reflecting an increase of 3.13% QoQ from Rs 4,378.45 lakh in Q3FY26, and an increase of 15.53% YoY from Rs 3,908.38 lakh in Q4FY25.
  • Annual Total Income: For the full year FY26, Total Income stood at Rs 16,825.09 lakh, higher by 9.80% YoY compared to Rs 15,323.23 lakh in FY25.
  • Net Profit After Tax: Net Profit for Q4FY26 was Rs 1,089.12 lakh, marking a decline of 12.62% QoQ compared to Rs 1,246.46 lakh in Q3FY26, and a decrease of 9.22% YoY against Rs 1,199.81 lakh in Q4FY25.
  • Annual Net Profit: For FY26, the Net Profit stood at Rs 4,668.15 lakh, down by 4.29% YoY compared to Rs 4,877.17 lakh in FY25.
  • Total Comprehensive Income: Total Comprehensive Income for Q4FY26 was reported at Rs 1,089.54 lakh, and for the full year FY26, it amounted to Rs 4,668.65 lakh.
  • Earnings Per Share (EPS): Basic and Diluted EPS for Q4FY26 was Rs 1.00, compared to Rs 1.14 in Q3FY26 and Rs 1.10 in Q4FY25. For the full year FY26, the EPS stood at Rs 4.28, compared to Rs 4.48 in FY25.

Business & Segment Highlights:

  • Dividend: The Board of Directors recommended a final dividend of Re 0.67 (67%) per equity share having a face value of Re 1 each, aggregating to Rs 7,30,06,728 for FY26, subject to the approval of shareholders at the ensuing Annual General Meeting.
  • Segment Performance: The company operates only in one Business Segment, i.e., manufacturing of fermentation-based pharmaceutical intermediates and APIs. Hence, there are no reportable segments as per Ind AS-108, and the financial results fully reflect the performance of this single segment.
  • Preferential Issue: The Board considered and approved a proposal for the preferential issue of equity shares to Non-Promoters. A Preferential Issue Committee has been constituted to decide and finalize the terms and conditions of the proposed issue.
  • Statutory Updates: The company recognized an incremental impact of Rs 14.49 lakh in the financial results due to the assessment of financial impacts arising from the new Labour Codes notified by the Government of India.
  • Key Appointments: The Board approved the appointment of M/s. Raja Dutta & Co., Cost Accountants as the Cost Auditor of the company for FY27.

Result PDF

Pharmaceuticals company Gujarat Themis Biosyn announced Q3FY26 results

  • Revenue: Rs 4,336.82 lakh against Rs 3,951.98 lakh during Q3FY25, change 10%.
  • PBT: Rs 1,687.34 lakh against Rs 1,740.04 lakh during Q3FY25, change -3%.
  • PAT: Rs 1,246.46 lakh against Rs 1,297.23 lakh during Q3FY25, change -4%.
  • EPS: Rs 1.14 for Q3FY26.

Result PDF

Pharmaceuticals company Gujarat Themis Biosyn announced Q4FY23 & FY23 results:

  • Q4FY23:
    • Revenue from Operations stood at Rs 28.17 crore in Q4FY23, as against Rs 28.76 crore in Q4FY22
    • EBITDA for the quarter was Rs 14.93 crore as against Rs 13.08 crore in Q4FY22, increase of 14.12%.
    • EBITDA Margin stood at 52.98%, up by 751 bps
    • Q4FY23 PAT stood at Rs 11.69 crore as against profit of Rs 9.79 crore in Q4FY22
    • EPS for the quarter stood at Rs 8.05
  • FY23:
    • Revenue from Operations stood at Rs 148.97 crore in FY23, vs Rs 114.85 crore in FY22, up 29.71%
    • EBITDA for FY23 was Rs 74.22 crore as against Rs 58.05 crore in FY22, increase of 27.86%
    • EBITDA Margin stood at 49.82%
    • FY23 PAT stood at Rs 57.97 crore as against PAT of Rs 43.62 crore in FY22
    • EPS for the year stood at Rs 39.90

 

 

Result PDF

Pharmaceutical company Gujarat Themis Biosyn announced Q2FY23 results:

  • Q2FY23 vs Q2FY22:
    • Revenue from operations stood at Rs 47.7 crore in Q2 FY23, as against Rs 35.1 crore in Q2 FY22, rise of 36.1%
    • EBITDA for the quarter was Rs 24.4 crore as against Rs 18.5 crore in Q2 FY22, an increase of 32.3% - EBITDA Margin stood at 51.2%
    • Q2 FY23 Profit stood at Rs 18.7 crore as against profit of Rs 13.8 crore in Q2 FY22
    • EPS for the quarter stood at Rs 12.87
  • H1FY23 vs H1FY22:
    • Revenue from operations stood at Rs 92.6 crore in H1 FY23, as against Rs 67.5 crore in H1 FY22, rise of 37.3%
    • EBITDA for the six months was Rs 47.2 crore as against Rs 35.2 crore in H1 FY22, an increase of 34.2% - EBITDA Margin stood at 50.9%
    • H1FY23 Profit stood at Rs 36.5 crore as against a profit of Rs 26.7 crore in H1 FY22
    • EPS for the period stood at Rs 25.10

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app